Vivek Subbiah: Final day of World Pancreatic Cancer Awareness Month
Vivek Subbiah shared a post on X:
“Today is the final day of World Pancreatic Cancer Awareness Month!
Would like to thank Anirban Maitra, Sharon Pine, EIC of Carcinogenesis, David Tuveson, Cold Spring Harbor Laboratory and Christine Alewine, National Cancer Institute for helping put together a series of articles on pancreatic cancer in honor of late researcher Perwez Hussain and inviting me to write on ‘Redefining pancreatic cancer management with tumor-agnostic precision medicine.’
Redefining pancreatic cancer management with tumor-agnostic precision medicine
Authors: Neha K Reddy, Vivek Subbiah.
The evolving role for surgery in pancreatic cancer
Authors: David Tuveson, Peter Allen.
Authors: Sarah Graham, Mariia Dmitrieva, Debora Barbosa Vendramini-Costa, Ralph Francescone, Maria A Trujillo, Edna Cukierman, Laura D Wood.
CAFomics: convergence to translation for precision stroma approaches
Authors: Ian C McCabe, Xianlu L Peng, Joseph F Kearney, Jen Jen Yeh.
Exogenous or in situ vaccination to trigger clinical responses in pancreatic cancer
Authors: Gregory L Beatty, Elizabeth M Jaffee.”
Vivek Subbiah is the Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute (USA). He is the former Executive Director of Oncology Research and former Associate Professor in the Department of Investigational Cancer Therapeutics at the MD Anderson Cancer. He focuses on translational cancer research and the design and implementation of early-phase biomarker-driven clinical trials. His work specifically targets antibody-drug conjugates, radiopharmaceuticals, immunoconjugates, and basket trials. He has also received the Yvonne Award 2024 by OncoDaily in the “Voice of Oncology” category.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023